The epidemiology of pulmonary arterial hypertension (PAH) has changed over the last
decade. Remarkable advances in understanding the pathobiology and clinical care required …

Background Targeting short-term improvements in multicomponent risk scores for mortality
in patients with pulmonary arterial hypertension (PAH) could result in improved long-term …

Ryan et al Pulmonary Arterial Hypertension Trials 115 for enrollment. 20 This, in turn,
increases the probability that a study cohort includes a heterogeneous range of PAH …

Pulmonary arterial hypertension (PAH) is predominantly a disease of women, with ratios of
4: 1 in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL …

Objectives This study assessed pulmonary hypertension (PH)-related hospitalizations,
including readmissions, among US patients with pulmonary arterial hypertension (PAH), a …

It is widely known that the incidence of pulmonary arterial hypertension (PAH) is higher in
female, whereas prognosis is poorer in male patients. However, sex differences in …

We have witnessed significant advances in the management of pulmonary arterial
hypertension (PAH)(1), a rare and severe condition characterized by intense pulmonary …

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal
disease associated with considerable overall clinical and economic burden. Although the …

BACKGROUND: Although pulmonary arterial hypertension (PAH) is widely accepted as
deadly, if not a rare disease, its prognostic impact beyond reports from specialist centres is …

Background and objective Pulmonary arterial hypertension (PAH) is a rare and fatal
disease. Data from Asia are lacking compared with the West. We aim to describe disease …